Probing Cancer: Immunotherapy and Molecular Imaging

Dr Robins researches novel immune checkpoint inhibitor (ICI) therapies.

The Singapore-based Cancer ImmunoTherapy Imaging (CITI) programme is a Singapore-wide collaborative research group, comprising 12 research institutes. CITI’s efforts are focused on the discovery and application of peptide-based imaging probes, which target immunotherapy treatment response biomarkers. Dr Edward G Robins, Head of Radiochemistry at the Singapore Bioimaging Consortium and Deputy Director of the NUS Clinical Imaging Research Centre, alongside his […]

Read More…

Novel imaging technique could lead to early diagnosis of lung cancer

Novel imaging technique could lead to early diagnosis of lung cancer

Non-small cell lung cancer is one of the most widespread forms of the disease. As with many other cancers, the best chance of survival comes with early diagnosis; unfortunately, at present this often doesn’t happen. In research that has the potential to improve the prognosis of lung cancer patients, Dr Claudio Scafoglio and colleagues at the University of California, Los […]

Read More…

New Toolkits for Positron Emission Tomography

PET scanners make use of radioactive tracers.

Positron emission tomography (PET) is a powerful imaging technique that uses radiotracers injected into the body to look at biology in tissues and cells, making it an important tool in biomedical research and drug development. Dr Victor Pike, Chief of the PET Radiopharmaceutical Sciences Section of the Molecular Imaging Branch at the National Institute of Mental Health in the U.S., […]

Read More…

On Hadron Deformation
Shaping our understanding of the proton

On Hadron Deformation Shaping our understanding of the proton

The proton is the smallest particle known to science that can exist in isolation and has a size but, until now, the shape of the proton has been little more than a guessing game. Professor C.N. Papanicolas, Academician and President of the Cyprus Institute and his team have helped to change that—and provided us with a new understanding of this most important […]

Read More…

Advances in CNS drug development

Advances in CNS drug development

The global prevalence of diseases affecting the central nervous system (CNS) demands the development of efficacious therapies for these unmet needs. However, drug development for CNS diseases is complicated by a limited ability to measure whether a drug candidate is accessing and affecting the human brain, particularly in early-stage human trials. Research by Dr Eugenii (Ilan) Rabiner and his colleagues: Dr […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION